Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

References

• Rai KR, Peterson BL, Applebaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl .7 Med 2000;343: 1750–7.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Robertson LE, O'Brien S et al. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymph 1995;18:493–6.
   Google Scholar
• Keating MJ, O'Brien S, Kantarijan H et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81:2878–84.
   Google Scholar
• Flinn IW, Byrd JC, Morrison C et al. Iludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000;96:71–5.
   PubMed Web of Science ®Google Scholar
• Keating M, O'Brien S, Lerner S et al. Combination chemo-antibody therapy with fludarabine, cyclophosphamide, and rituximab achieves high CR rate in previously untreated chronic lymphocytic leukemia. Blood 2000;96:514a.
   Google Scholar
• Keating MJ, Byrd J, Rai K et al. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine. Blood 1999;94:705a.
   Web of Science ®Google Scholar
• Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. y Clin Oncol 1994;12:748–58.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Przepiorka D, van Besien K et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br 7 Hematol 1997;97: 466–73.
   Google Scholar
• Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood-stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997;19:455–60.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. y Am Stat Assoc 1958;53:457–81.
   Web of Science ®Google Scholar
• Khouri I, Keating MJ, Champlin RE. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hemato/1998;5:454–9.
   Google Scholar
• Rondon G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996;18:699–72.
   PubMed Web of Science ®Google Scholar
• Michallet M, Archimbaud E, Bandini G et al. HLA-identi-cal sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996; 124:311–15.
   PubMed Web of Science ®Google Scholar
• Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993;82:1366–76.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra A et al. Limiting trans-plantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071–7.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Greyer M et al. Guidelines for chronic lymphocytic leukemia: Revised guidelines for diag-nosis and treatment: NCI-sponsored working group. Blood 1996;87:4990–7.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A et al. Genomic aberra-tions and survival in chronic lymphocytic leukemia. N Engl .7 Med 2000;343: 1910–16.
   Google Scholar
• Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expres-sion and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023–9.
   PubMed Web of Science ®Google Scholar
• Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmye-loablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol1999:11;87–95.
   PubMedGoogle Scholar
• Khouri IF, Keating MK, Korbling M et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment of lymphoid malignancies. y Gun Oncol 1998;16:2817–24.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba R, Giralt SA et aL Nonablative allogeneichematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001:98;3595–99.
   PubMed Web of Science ®Google Scholar
• Khouri I, Munsell M, Yajzi S et al. Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia: the case for early interven-tion. Blood 2000;96:205a.
   Web of Science ®Google Scholar